In oesophageal squamous cell carcinoma, defactinib targets the PI3K/AKT pathway to inhibit malignancy [68], and in non-small cell lung cancer (NSCLC), it has shown potential in treating KRAS-mutated tumors when combined with other agents like D-PROTACs [69]. Here, KRAS is linked to non-small cell lung carcinoma.